Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2023-11-14

Original market date: See footnote 1

2023-11-14

Product name:

IMVEXXY

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02503689

Product Monograph/Veterinary Labelling:

Date: 2020-08-13 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

KNIGHT THERAPEUTICS INC.
1055 3400 De Maisonneuve Blvd W
Montreal
Quebec
Canada H3Z 3B8

Class:

Human

Dosage form(s):

Insert

Route(s) of administration:

Vaginal

Number of active ingredient(s):

1

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

68:16.04 

Anatomical Therapeutic Chemical (ATC): See footnote 4

G03CA03 ESTRADIOL

Active ingredient group (AIG) number:See footnote5

0106457038

List of active ingredient(s)
Active ingredient(s) Strength
ESTRADIOL (ESTRADIOL HEMIHYDRATE) 4 MCG / INSERT
Version 4.0.2
Date modified: